IHVR-19029 is a potent inhibitor of endoplasmic reticulum α-glucosidase I and II (α-glucosidases I/II), with IC50 of 0.48 μM for ER α-glucosidase I. IHVR-19029 effectively blocks the replication of several hemorrhagic fever viruses, like dengue virus, Ebola virus and Rift Valley fever virus. IHVR-19029 and Favipiravir combine to enhance anti-viral effect.

Physicochemical Properties

Molecular Formula	C23H43N3O5
Molecular Weight	441.604626893997
Exact Mass	443.335
CAS #	1447464-73-4
PubChem CID	71713800
Appearance	Off-white to light yellow solid powder
LogP	1.7
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	10
Heavy Atom Count	31
Complexity	536
Defined Atom Stereocenter Count	4
SMILES	O=C(NC(C)(C)C)N(CCCCCCN1[C](CO)[C@H]([C]([C@H](C1)O)O)O)C1CCCCC1 |^1:15,19|
InChi Key	GFBNIASMQRMEDU-PLACYPQZSA-N
InChi Code	InChI=1S/C23H45N3O5/c1-23(2,3)24-22(31)26(17-11-7-6-8-12-17)14-10-5-4-9-13-25-15-19(28)21(30)20(29)18(25)16-27/h17-21,27-30H,4-16H2,1-3H3,(H,24,31)/t18-,19+,20-,21-/m1/s1
Chemical Name	3-tert-butyl-1-cyclohexyl-1-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]hexyl]urea
Synonyms	IHVR19029; IHVR 19029; IHVR-19029
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	With EC50 values of 0.25, 0.74, and 1.25 μM, respectively, IHVR-19029 may efficiently suppress the dengue virus (DENV), Takarib virus (TCRV), and bovine viral diarrhea virus (BVDV) [2]. IHVR-19029 and Favipiravir work in concert to suppress the replication of Ebola and yellow fever viruses in cultured cells [4].
ln Vivo	IHVR-19029 (25-75 mg/kg; i.p.; twice daily for 10 days) suppresses EBOV and MARV infection in mice [2]. The AUC, C0, T1/2, CL and Vd values of IHVR-19029 (5 mg/kg; iv) are 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg and 3.0 L/ kg, respectively[2]. The AUC value of IHVR-19029 (75/5/5 mg/kg; po/im/ip) is 945/1839/983 μg*h/mL, the Cmax value is 0.26/1.23/1.33 μg/ml, and the Tmax value is 2.1 /0.1/0.17 hours, the F values are 4.6/71/133% respectively[2].
Animal Protocol	Animal/Disease Models: balb/c (Bagg ALBino) mouse (12 weeks 233 years old) (MARV infection) [2] Doses: 25, 75 mg/kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily until day 10 Experimental Results: Observed effects on Marburg Virus (MARV)-induced death was Dramatically protective. Animal/Disease Models: C57B1/6 mice (8-12 weeks old) (EBOV infection) [2] Doses: 25, 75 mg/kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily for 10 days Experimental Results: Significant effects were observed survival rate.
References	[1]. Meeting report: 31st International Conference on Antiviral Research. Antiviral Res. 2018 Oct;158:88-102. [2]. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98(3):432‐440. [3]. Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.ACS Med Chem Lett. 2017 Jan 17;8(2):157-162. [4]. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018 Feb;150:112-122.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~225.42 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2645 mL	11.3225 mL	22.6449 mL
	5 mM	0.4529 mL	2.2645 mL	4.5290 mL
	10 mM	0.2264 mL	1.1322 mL	2.2645 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.